Metabolic syndrome is defined as cluster of independent risk factors of coronary 
heart disease and type 2 diabetes mellitus including prediabetic glucose 
metabolism disorders associated with insulin resistance as impaired fasting 
glucose, impaired glucose tolerance and/ or borderline increasing of 
glycosylated haemoglobin; central obesity, atherogenic dyslipidaemia with 
increasing of triglyceride levels and decreasing of high density lipoprotein 
levels and hypertension. In diagnosis of prediabetic states there are used 
fasting glycaemia, 2 hours glycaemia during oral glucose tolerant test and HbA1c 
level, which importance in diagnostic is discussed. In DM2 prevention there is 
important mainly physical activity at least 30 min daily. In the case of 
pharmacotherapy there was confirmed efficiency of metformin, which could be used 
in states with high risk of DM2 conversion and some antihypertensive drugs, 
mainly sartans. In the case of treatment of dyslipidaemia by statins there is 
moderate increased risk of DM2 in prediabetic states, but cardiovascular benefit 
from treatment some times exceeds this risk.